All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

U.S. FDA fast-tracks approval of MWTX-003 for the treatment of PV

Sep 25, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in polycythemia vera.

Bookmark this article

High iron levels are a known complicator of survival and overall quality of life for patients with PV. On September 20, 2023, the United States Food and Drug Administration granted fast-track designation to MWTX-003, an investigational anti-transmembrane serine protease 6 (TMPRSS6) monoclonal antibody designed to increase hepcidin levels and, thereby, reduce serum iron levels in patients with polycythemia vera (PV).

Preclinical data have highlighted strong pharmacodynamic effects, with a single dose resulting in a 70% reduction in serum iron levels for 21 days. Moreover, a related β-thalassemia clinical model demonstrated a 4-fold increase in hepcidin levels, a 60–65% reduction in serum and liver iron, increased red blood cell production, and a decrease in spleen weight. A phase I proof-of-mechanism trial is to begin in the second half of 2023. Further plans for a phase 1b/2a proof-of-concept study evaluating the safety and pharmacokinetic profile of MWTX-003 in patients with PV are also in place.

  1. Rosa, K. MWTX-003 Wins FDA Fast Track Designation for Polycythemia Vera. Onclive. Published Sep 21, 2023. Accessed Sep 25, 2023.


Subscribe to get the best content related to MPN delivered to your inbox